Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy

Table 1

Baseline characteristics of both groups (N-irAE and DD) in comparison.

	N-irAEs group (n = 20)	DD group (n = 11)	-value
Mean age, years (range)	66 (23–89)	69 (51–82)	0.626
Sex (males), n (%)	13/20 (65)	7/11 (64)	0.943
Latency: ICI therapy first administration, first neurological symptoms (days, mean, and ranges)	137 (30–153)	235 (30–671)	0.233
Latency: ICI therapy last administration, first neurological symptoms (days, mean, and ranges)	13.1 (1–37)	25 (6–70)	0.115
Elevated CRP at manifestation of neurological symptoms, n (%)	10/20 (50)	2/11 (18)	0.100
Elevated WBC at manifestation of neurological symptoms, n (%)	6/20 (30)	2/11 (18)	0.563
Fever at manifestation of neurological symptoms, n (%)	2/20 (10)	0/11 (0)	0.163

Data are presented as mean value and range. DD: differential diagnoses; f: female; ICI: immune checkpoint inhibitor; m: male; n.c.: not calculated; N-irAEs: neurological adverse events; WBC: white blood cell count.